Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202

BACKGROUND: In prostate cancer, end points that reliably portend prognosis and treatment benefit (surrogate end points) can accelerate therapy development. Although surrogate end point candidates have been evaluated in the context of radiotherapy and short-term androgen deprivation (AD), potential s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Dignam, James J., Hamstra, Daniel A., Lepor, Herbert, Grignon, David, Brereton, Harmar, Currey, Adam, Rosenthal, Seth, Zeitzer, Kenneth L., Venkatesan, Varagur M., Horwitz, Eric M., Pisansky, Thomas M., Sandler, Howard M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2019
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6338393/
https://ncbi.nlm.nih.gov/pubmed/30526194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00154
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi